期刊
CANCER DISCOVERY
卷 8, 期 8, 页码 935-943出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-17-1178
关键词
-
类别
资金
- UCLA/Caltech Medical Scientist Training Program
- NIH National Research Service Award [CA183220]
- NIH [R35 CA197633, P01 CA168585]
- Parker Institute for Cancer Immunotherapy
- Ressler Family Fund
- Samuels Family Fund
- Grimaldi Family Fund
- Garcia-Corsini Family Fund
- National Institutes of Health [P30 CA016042, 5P30 AI028697]
A promising arsenal of targeted and immunotherapy treatments for metastatic melanoma has emerged over the last decade. With these therapies, we now face new mechanisms of tumor-acquired resistance. We report here a patient whose metastatic melanoma underwent dedifferentiation as a resistance mechanism to adoptive T-cell transfer therapy (ACT) to the MART1 antigen, a phenomenon that had been observed only in mouse studies to date. After an initial period of tumor regression, the patient presented in relapse with tumors lacking melanocytic antigens (MART1, gp100) and expressing an inflammation-induced neural crest marker (NGFR). We demonstrate using human melanoma cell lines that this resistance phenotype can be induced in vitro by treatment with MART1 T cell receptor-expressing T cells or with TNF alpha, and that the phenotype is reversible with withdrawal of inflammatory stimuli. This supports the hypothesis that acquired resistance to cancer immunotherapy can be mediated by inflammation-induced cancer dedifferentiation. SIGNIFICANCE: We report a patient whose metastatic melanoma underwent inflammation-induced dedifferentiation as a resistance mechanism to ACT to the MART1 antigen. Our results suggest that future melanoma ACT protocols may benefit from the simultaneous targeting of multiple tumor antigens, modulating the inflammatory response, and inhibition of inflammatory dedifferentiation-inducing signals. (c) 2018 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据